Evidence map›Paper›PMID 38033993›Full record

ArticleFrontiers in endocrinology2023

Following in Banting's footsteps or straying from the path? Observations from contemporary diabetes innovation.

Connor Leadley, Ananta Addala, Juliet Berkeley, Hamish Crocket, Elizabeth A Davis, Niranjala Hewapathirana, Sufyan Hussain, Rayhan Lal, Kate Lomax, Thomas Wilkinson and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in endocrinology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 5 countries.

Connor LeadleyDepartment of Pediatrics, University of Otago, Christchurch, New Zealand.
Ananta AddalaDivision of Endocrinology, Department of Pediatrics, Stanford University, Stanford, United States.
Juliet BerkeleyDepartment of Diabetes and Endocrinology, Te Whatu Ora Waitaha, Christchurch, New Zealand.
Hamish CrocketTe Huataki Waiora School of Health, University of Waikato, Hamilton, New Zealand.
Elizabeth A DavisDepartment of Endocrinology and Diabetes, Perth Children's Hospital, Perth, WA, Australia.
Niranjala HewapathiranaDepartment of Diabetes and Endocrinology, Te Whatu Ora Waitaha, Christchurch, New Zealand.
Sufyan HussainDepartment of Diabetes and Endocrinology, Guy's & St Thomas' National Health Service (NHS) Foundation Trust, London, United Kingdom.
Rayhan LalDivision of Endocrinology, Department of Pediatrics, Stanford University, Stanford, United States.
Kate LomaxDepartment of Endocrinology and Diabetes, Perth Children's Hospital, Perth, WA, Australia.
Thomas WilkinsonDepartment of Pediatrics, University of Otago, Christchurch, New Zealand.
Martin de BockDepartment of Pediatrics, University of Otago, Christchurch, New Zealand.
Marie-Anne BurckhardtPediatric Endocrinology and Diabetology, University Children's Hospital, Basel, Switzerland.
University of Otago · NZPerth Children's HospitalStanford University · USKings Health Partners · GBUniversity of Basel · CHUniversity of Waikato · NZ

Funding

NIDDK NIH HHS K23 DK122017
6 · The paper itself

Abstract

While advancements in the treatment of diabetes continue to rapidly evolve, many of the newer technologies have financial barriers to care, opposing the egalitarian ethos of Banting who sold his patent on insulin for a nominal cost to allow it to be made widely available. Inequity in access to new therapies drives disparity in diabetes burden with potential for these gaps to widen in the future. The 2023 International Conference on Advanced Technologies and Treatments of Diabetes (ATTD) presented ground-breaking and current research in diabetes technology. Oral presentations of the ATTD conference 2023 were analyzed to describe what percentage of speakers discussed equity in their talks. Overall, less than a quarter of presenters discussed equity, though there was regional variation. To ensure that diabetes technologies reduce disparity and improve outcomes, we encourage future speakers at diabetes (technology) conferences to consider equity of diabetes care and incorporate this into their presentations.

Indexed as

Diabetes MellitusHumansInsulinInsulinconferencediabetes technologyequitytype 1 diabetestype 2 diabetes

Identifiers

PMID38033993
PMCPMC10686253
OpenAlexW4388671819

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.